Algernon Pharmaceuticals Inc. C.AGN

Chronic Cough: Algernon versus Bellus Health versus Merck

[C10H12N2]

Point Of Information: In regards to Algernon Pharmaceuticals Chronic Cough data, the CEO reported a 42% reduction in cough with no (0%) known taste disturbance. The CEO was being modest when he compared Algernon's preclinical taste disturbance data to Bellus Health. The fact is Bellus Health recently reported a 6.5% taste disturbance with their Chronic Cough drug.

Furthermore, to the best of my knowledge, Bellus Health recently reported data is targeted at Chronic Cough patients with 25 or more coughs per hour. However, Chronic Cough patients fall into the range of a minimum 10 coughs per hour. Thus, there is a huge number of unmet Chronic Cough patients at 10 to 24 coughs per hour. Meaning, a vast number of Chronic Cough patients will still experience an unmet need if Bellus Health and/or Merck receives market approval in the future.

Merck's drug is still trying to jump over hurdles with FDA market approval.

Bellus Health thuis far plans a Phase 3 clinical trial in the second half of 2022.

Will Algernon Pharmaceuticlas launch a Phase 2b Chronic Cough clinical trial in 2022?

I guess that would be a question for the CEO come next week.

Personally, I hope the Chronic Cough study does not happen before the end of this year.

Get the stock price up up up (above 30 $ US) before diluting/looting the company like Pirates @ Sea



All of the above is my opinion based on publicly available information.